GeoVax Labs, Inc. (Nasdaq: GOVX) is advancing its oncology program Gedeptin toward a Phase 2 clinical trial and potential strategic partnerships, positioning the therapy as a combination agent alongside immune checkpoint inhibitors (ICIs) in the evolving oncology landscape.
The Atlanta-based clinical-stage biotechnology company outlined its development milestones and strategic priorities, emphasizing Gedeptin’s potential integration into established treatment regimens. With oncology increasingly defined by combination approaches, GeoVax believes Gedeptin’s ability to work with ICIs could enhance its clinical and commercial prospects.
GeoVax is preparing to initiate a Phase 2 trial evaluating Gedeptin in combination with an ICI as a first-line neoadjuvant treatment for patients with resectable locally advanced head and neck cancer, with trial initiation targeted for 2027. The study will assess tumor response, biomarker-driven immune activation, and event-free survival outcomes—a key step in establishing clinical validation for Gedeptin in combination immuno-oncology strategies.
Beyond head and neck cancer, GeoVax plans to advance preclinical and translational work to evaluate Gedeptin across additional solid tumor indications. These efforts aim to identify tumor settings where combination approaches may provide the greatest clinical benefit and inform future development strategies.
“We are entering an important phase of development for Gedeptin, with a focus on clinical execution and advancing discussions around potential partnerships,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “As combination therapy becomes more common across oncology, we believe Gedeptin is well positioned to be integrated into these regimens and contribute to improved treatment outcomes.”
GeoVax is actively pursuing opportunities to advance Gedeptin through clinical development partnerships, combination-focused collaborations, and potential licensing or co-development arrangements. The company has built a clinical and scientific foundation to support Gedeptin’s next stage, including completed Phase 1/2 clinical experience in advanced head and neck cancer, an Oncology Advisory Board with deep immuno-oncology expertise, and expanded intellectual property supporting combination use with checkpoint inhibitors.
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase. Following administration of a systemically delivered prodrug, the encoded enzyme converts the prodrug into a cytotoxic agent directly within the tumor microenvironment.
GeoVax’s broader pipeline includes GEO-MVA, a vaccine targeting mpox and smallpox advancing under an expedited regulatory pathway with a planned pivotal Phase 3 trial in the second half of 2026, and GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised populations. For more information, visit www.geovax.com.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax Advances Gedeptin Toward Phase 2 Trials and Seeks Partnership Opportunities.